Open main menu

HemOnc.org - A Hematology Oncology Wiki β

Melanoma, NRAS-mutated

Section editor
Bethbuchbinder.jpg
Elizabeth Buchbinder, MD
Dana-Farber Cancer Institute
Boston, MA

LinkedIn

Note: these are regimens tested in biomarker-specific populations, please see the main melanoma page for other regimens.

2 regimens on this page
2 variants on this page


Contents

Advanced or metastatic disease, TKI-naive

Binimetinib monotherapy

back to top

Regimen

Study Evidence Comparator Comparative Efficacy
Ascierto et al. 2013 Phase II
Dummer et al. 2017 (NEMO) Phase III (E-switch-ooc) Dacarbazine Superior PFS

Chemotherapy

Biomarker eligibility criteria

  • Gene: NRAS or BRAF
  • Alteration: mutation [Val600 BRAF]


References

  1. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, Dummer R. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013 Mar;14(3):249-56. Epub 2013 Feb 13. link to original article contains protocol PubMed
  2. NEMO: Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Apr;18(4):435-445. Epub 2017 Mar 8. link to original article contains protocol PubMed

Dacarbazine monotherapy

back to top

Regimen

Study Evidence Comparator Comparative Efficacy
Dummer et al. 2017 (NEMO) Phase III (C) Binimetinib Inferior PFS

Chemotherapy

21-day cycles

References

  1. NEMO: Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, Queirolo P, Wasserman E, Ford J, Weill M, Sirulnik LA, Jehl V, Bozón V, Long GV, Flaherty K. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Apr;18(4):435-445. Epub 2017 Mar 8. link to original article contains protocol PubMed